Consumer rights & well-being

A person repairing a smartphone circuit board for an article about right to repair laws

Right to repair laws have now been introduced in all 50 U.S. states

By / / Good News For Humankind

Right to repair legislation has now been introduced in all 50 U.S. states, marking a historic milestone for the consumer rights movement. In 2025, five states — New York, California, Minnesota, Oregon, and Colorado — passed laws requiring manufacturers to provide independent shops and individual owners with the parts, tools, and documentation needed to fix their own devices and equipment. This matters because it breaks the manufacturer-controlled repair monopoly that has driven up costs, reduced competition, and accelerated electronic waste. The milestone reflects eleven years of broad, bipartisan grassroots organizing — and with active bills in 24 states, momentum is only growing.

Medications, for article on Medicare drug price negotiation

The U.S. negotiates Medicare drug price cuts that will save billions for U.S. citizens

By / / Good News For Humankind

Medicare drug price negotiation just delivered its first results, and the projected savings land at roughly $6 billion a year once new prices take effect in January 2026. After nearly six decades of being legally barred from bargaining with drugmakers, Medicare negotiated discounts on 10 widely used medications, including the blood thinner Eliquis and the diabetes drug Januvia. Some prices dropped by as much as 79%, with the deepest cuts going to drugs that faced the least competition. Around 9 million enrollees use these medications, and a new $2,000 annual cap on out-of-pocket drug costs adds further relief. Beyond the dollars, this shifts what’s politically possible — moving the U.S. closer to how most wealthy democracies have long approached medicine pricing.

Pills spilling out of pill bottle, for article on march-in rights policy

U.S. sets policy to seize patents of government-funded drugs if price deemed too high

By / / Good News For Humankind

Drug patent seizures are back on the table for the first time in over 40 years, with the Biden administration releasing a draft roadmap that explicitly lets the federal government license out medicines to competitors when companies charge prices most Americans can’t afford. The power has existed since 1980 but was never used or even defined — until now. Price itself is now a factor: if a drug was built on taxpayer-funded research through agencies like the NIH, and the company sells it out of reach of ordinary patients, generics could be authorized. Even as a credible threat, this reframes who publicly funded science is really for — and could shift drug pricing fights well beyond U.S. borders.